Long-term treatment of patient with metastatic melanoma of the trunk

被引：0

作者：

Kempa-Kaminska, Natasza ^{[1
]}

机构：

[1] Dolnoslaskie Ctr Onkol Wroclawiu, Oddzial Onkol Klin, Pl Hirszfelda 12, PL-53413 Wroclaw, Poland

来源：

ONCOLOGY IN CLINICAL PRACTICE | 2018年 / 14卷

关键词：

immunotherapy; melanoma; vemurafenib; hepatotoxicity;

D O I：

10.5603/OCP.2018.0063

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Currently there has been a huge development in melanoma therapy. There are drugs with high efficacy, but also with a completely new toxicity profile. Below is a case report of a patient treated for metastatic melanoma of the body. Treatment included vemurafenib and immunotherapy in the form of pembrolizumab, a monoclonal antibody blocking PD-1 receptor. Among toxicity, dermatological effects of vemurafenib treatment and hepatotoxicity during immunotherapy were observed mainly in case of treatment with vemurafenib. The applied treatment allowed for several years of survival of the patient in good general condition.

引用

页码：A19 / A22

页数：4

共 50 条

[31] Long-term survival with modern therapeutic agents against metastatic melanoma—vemurafenib and ipilimumab in a daily life setting
B. M. Lang
A. Peveling-Oberhag
D. Faidt
A. M. Hötker
V. Weyer-Elberich
S. Grabbe
C. Loquai
Medical Oncology, 2018, 35
[32] Efficacy and Safety of the Long-term Treatment of Melanoma with a Mistletoe Preparation (Iscador)
Grossarth-Maticek, Ronald
Ziegler, Renatus
SCHWEIZERISCHE ZEITSCHRIFT FUER GANZHEITSMEDIZIN, 2007, 19 (06): : 325 - 332
[33] Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival
Khammari, Amir
Knol, Anne-Chantal
Nguyen, Jean-Michel
Bossard, Celine
Denis, Marc-Guillaume
Pandolfino, Marie-Christine
Quereux, Gaelle
Bercegeay, Sylvain
Dreno, Brigitte
JOURNAL OF IMMUNOLOGY RESEARCH, 2014, 2014 : 186212
[34] Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment
Cybulska-Stopa, Bozena
Piejko, Karolina
Ostaszewski, Krzysztof
Dziura, Robert
Galus, Lukasz
Ziolkowska, Barbara
Kempa-Kaminska, Natasza
Zietek, Marcin
Bal, Wieslaw
Kamycka, Agnieszka
Dudzisz-Sledz, Monika
Kubiatowski, Tomasz
Kaminska-Winciorek, Grazyna
Suwinski, Rafal
Mackiewicz, Jacek
Czarnecka, Anna Malgorzata
Rutkowski, Piotr
MELANOMA RESEARCH, 2023, 33 (03) : 208 - 217
[35] Systemic treatment for metastatic renal cell carcinoma and long-term results
Brinkmann, OA
Roigas, J
Hertle, L
UROLOGE A, 2002, 41 (03): : 231 - 238
[36] Long-term Response After Stopping Immunotherapy in a Patient With Metastatic Renal Cancer
Haineala, Bogdan
Zgura, Anca
Diaconu, Camelia
Mehedintu, Claudia
Bacinschi, Xenia
Anghel, Rodica Maricela
IN VIVO, 2021, 35 (03): : 1805 - 1810
[37] FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma
Dimitriou, F.
Lo, S. N.
Tan, A. C.
Emmett, L.
Kapoor, R.
Carlino, M. S.
Long, G., V
Menzies, A. M.
ANNALS OF ONCOLOGY, 2022, 33 (01) : 99 - 106
[38] High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update
Atkins, MB
Kunkel, L
Sznol, M
Rosenberg, SA
CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 2000, 6 : S11 - S14
[39] Long-term survival with modern therapeutic agents against metastatic melanoma-vemurafenib and ipilimumab in a daily life setting
Lang, B. M.
Peveling-Oberhag, A.
Faidt, D.
Hoetker, A. M.
Weyer-Elberich, V.
Grabbe, S.
Loquai, C.
MEDICAL ONCOLOGY, 2018, 35 (03)
[40] Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report
Lee, Jee Min
Mehta, Urvi N.
Dsouza, Ly H.
Guadagnolo, Beverly Ashleigh
Sanders, Deborah L.
Kim, Kevin B.
MELANOMA RESEARCH, 2013, 23 (02) : 175 - 178

← 1 2 3 4 5 →